BR112016009465A2 - Vírus herpes simplex oncolítico recombinante (ohsv), ácido nucleico o codificando, estoque viral e composição o compreendendo, bem como seu uso - Google Patents
Vírus herpes simplex oncolítico recombinante (ohsv), ácido nucleico o codificando, estoque viral e composição o compreendendo, bem como seu usoInfo
- Publication number
- BR112016009465A2 BR112016009465A2 BR112016009465A BR112016009465A BR112016009465A2 BR 112016009465 A2 BR112016009465 A2 BR 112016009465A2 BR 112016009465 A BR112016009465 A BR 112016009465A BR 112016009465 A BR112016009465 A BR 112016009465A BR 112016009465 A2 BR112016009465 A2 BR 112016009465A2
- Authority
- BR
- Brazil
- Prior art keywords
- ohsv
- herpes simplex
- simplex virus
- recombinant oncolytic
- oncolytic herpes
- Prior art date
Links
- 241000700584 Simplexvirus Species 0.000 title abstract 3
- 230000000174 oncolytic effect Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 108700011259 MicroRNAs Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000002679 microRNA Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16645—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
- C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16671—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
VÍRUS HERPES SIMPLEX ONCOLÍTICO RECOMBINANTE (OHSV), ÁCIDO NUCLEICO O CODIFICANDO, ESTOQUE VIRAL E COMPOSIÇÃO O COMPREENDENDO, BEM COMO SEU USO. A presente invenção proporciona um Vírus Herpes Simplex oncolítico recombinante (oHSV) que compreende um ligante não-HSV específico para uma molécula (proteínas, lipídios, ou determinante de hidrato de carbono) presente na superfície de uma célula (como uma célula cancerosa) e um ou mais cópias de uma ou mais sequências alvo microRNA inserido em um ou mais loci de genes de HSV, de preferência, um ou mais genes de HSV (s) necessárias para a replicação do HSV em células normais (isto é, não cancerosas). A invenção proporciona ainda existências e composições farmacêuticas que compreendem o inventivo oHSV e métodos para matar células de tumor, empregando a oHSV inventivo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361896497P | 2013-10-28 | 2013-10-28 | |
PCT/US2014/062676 WO2015066042A1 (en) | 2013-10-28 | 2014-10-28 | Oncolytic hsv vector |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016009465A2 true BR112016009465A2 (pt) | 2017-10-03 |
BR112016009465A8 BR112016009465A8 (pt) | 2018-01-30 |
Family
ID=53005031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016009465A BR112016009465A8 (pt) | 2013-10-28 | 2014-10-28 | vetor de hsv oncolítico. |
Country Status (18)
Country | Link |
---|---|
US (5) | US10201575B2 (pt) |
EP (3) | EP3778906A1 (pt) |
JP (3) | JP6588024B2 (pt) |
KR (2) | KR102330183B1 (pt) |
CN (2) | CN106068326B (pt) |
AU (1) | AU2014342465B2 (pt) |
BR (1) | BR112016009465A8 (pt) |
CA (1) | CA2928956A1 (pt) |
DK (1) | DK3184641T3 (pt) |
ES (2) | ES2781852T3 (pt) |
HK (1) | HK1225756A1 (pt) |
IL (2) | IL245312B (pt) |
MX (2) | MX2016005488A (pt) |
NZ (1) | NZ720021A (pt) |
PT (1) | PT3184641T (pt) |
RU (1) | RU2719190C2 (pt) |
SG (1) | SG11201603119RA (pt) |
WO (1) | WO2015066042A1 (pt) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011130749A2 (en) | 2010-04-16 | 2011-10-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors |
DK3184641T3 (da) | 2013-10-28 | 2020-08-03 | Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education | Onkolytisk hsv-vektor |
CN107406834B (zh) * | 2015-02-11 | 2021-03-16 | 生物工程大学精神物质实验室 | 具有糖蛋白h融合体的重靶向疱疹病毒 |
RU2749050C2 (ru) * | 2016-01-27 | 2021-06-03 | Онкорус, Инк. | Онколитические вирусные векторы и их применение |
US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
CN108884460B (zh) * | 2016-03-19 | 2023-04-28 | 埃克苏马生物技术公司 | 淋巴细胞转导及其扩增调节的方法与组合物 |
LT3377637T (lt) * | 2016-04-08 | 2020-07-10 | Krystal Biotech, Inc. | Kompozicijos, skirtos panaudoti žaizdų, sutrikimų ir odos ligų gydymo būduose |
EP3380621A4 (en) * | 2016-04-22 | 2019-05-08 | Immvira Co., Limited | CONSTRUCTION OF THE VECTOR OF OBLIGATES ONCOLYTIC HERPES SIMPLEX VIRUSES (OHSV) AND CANCER THERAPY CONSTRUCTIONS |
ES2904882T3 (es) * | 2016-04-29 | 2022-04-06 | Virogin Biotech Canada Ltd | Vectores de HSV con replicación mejorada en células cancerosas |
HUE053007T2 (hu) | 2016-06-09 | 2021-06-28 | Univ Bologna Alma Mater Studiorum | Herpeszvírus módosított D glikoproteinnel |
KR20190020727A (ko) | 2016-06-09 | 2019-03-04 | 알마마 테르 스투디오룸 유니베르시타‘ 디 볼로냐 | 변형된 당단백질 b를 갖는 헤르페스 바이러스 |
US11427625B2 (en) | 2016-06-14 | 2022-08-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Expression of NKG2D activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells |
AU2017290828A1 (en) | 2016-06-30 | 2019-01-24 | Virogin Biotech Canada Ltd | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
GB201700350D0 (en) * | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
US20200000862A1 (en) * | 2017-02-03 | 2020-01-02 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic virus therapy |
CN108570455B (zh) * | 2017-03-09 | 2022-08-12 | 厦门大学 | 一种重组单纯疱疹病毒及其用途 |
EP3658165A4 (en) | 2017-07-26 | 2021-09-01 | Oncorus, Inc. | ONCOLYTIC VIRUS VECTORS AND USES THEREOF |
GB201714430D0 (en) * | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
EP3710018A4 (en) * | 2017-11-16 | 2022-03-09 | Virogin Biotech Canada Ltd | ONCOLYTIC VIRUSES DECORATED BY A TARGETING FRACTION |
EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
US20210252084A1 (en) * | 2018-04-13 | 2021-08-19 | Bluebird Bio, Inc. | Adoptive cellular therapy |
US20210121513A1 (en) * | 2018-05-31 | 2021-04-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Antigenically Stealthed Oncolytic Viruses |
KR101998793B1 (ko) * | 2018-09-04 | 2019-07-10 | 의료법인 성광의료재단 | 재조합 단순 헤르페스 바이러스의 제조를 위한 벡터 |
CN111117973A (zh) * | 2018-10-30 | 2020-05-08 | 中国科学院武汉病毒研究所 | 一种受microRNA调控的重组溶瘤肠道病毒71型及应用 |
TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
CN114765990A (zh) | 2019-10-10 | 2022-07-19 | 昂克诺斯公司 | 双重病毒和双重溶瘤病毒以及治疗方法 |
KR20210151002A (ko) * | 2020-06-03 | 2021-12-13 | 주식회사 젠셀메드 | HveC의 세포외 도메인과 암세포 표적화 영역의 융합 단백질을 발현할 수 있는 발현 카세트를 가지는 재조합 헤르페스 심플렉스 바이러스 및 그 용도 |
WO2021251589A1 (ko) * | 2020-06-12 | 2021-12-16 | 주식회사 젠셀메드 | 다중 표적화 재조합 헤르페스 심플렉스 바이러스 및 그 용도 |
JP7235334B2 (ja) * | 2020-11-26 | 2023-03-08 | イムヴィラ・カンパニー・リミテッド | 癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス(oHSV)偏性ベクター及びその構築体の構築 |
CA3213789A1 (en) | 2021-04-02 | 2022-10-06 | Krystal Biotech, Inc. | Viral vectors for cancer therapy |
CN114010666B (zh) * | 2021-10-22 | 2024-05-07 | 上海交通大学 | 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用 |
WO2023147566A1 (en) * | 2022-01-29 | 2023-08-03 | Virogin Biotech Canada Ltd | Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5244792A (en) | 1984-04-06 | 1993-09-14 | Chiron Corporation | Expression of recombinant glyoprotein B from herpes simplex virus |
JPH0668B2 (ja) | 1985-08-30 | 1994-01-05 | 財団法人化学及血清療法研究所 | 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド |
US5849572A (en) | 1990-10-10 | 1998-12-15 | Regents Of The University Of Michigan | HSV-1 vector containing a lat promoter |
US5879934A (en) | 1992-07-31 | 1999-03-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
GB9415369D0 (en) | 1994-07-29 | 1994-09-21 | Lynxvale Ltd | Mutant virus |
US6261552B1 (en) | 1997-05-22 | 2001-07-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus vectors |
GB9700411D0 (en) | 1997-01-10 | 1997-02-26 | Univ London | Eukaryotic gene expression cassette and uses thereof |
EP1002119A1 (en) | 1997-07-31 | 2000-05-24 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeted hsv vectors |
WO1999031241A1 (en) | 1997-12-17 | 1999-06-24 | Immunex Corporation | Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides |
EP1002864A1 (en) | 1998-11-10 | 2000-05-24 | Universita' degli studi di Bologna | HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections |
US6897057B1 (en) * | 1999-08-31 | 2005-05-24 | The General Hospital Corporation | Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression |
GB9930418D0 (en) | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
EP1381280B1 (en) * | 2001-03-27 | 2011-05-11 | Catherex, Inc. | Viral vectors and their use in therapeutic methods |
DE60232742D1 (de) | 2001-10-04 | 2009-08-06 | Immunex Corp | Ul16-bindungsprotein 4 |
KR100900249B1 (ko) | 2001-12-07 | 2009-05-29 | 포항공과대학교 산학협력단 | SIVmac239의 면역원성 플라스미드 및 이들을 함유한AIDS DNA 백신 |
AU2003216502B2 (en) | 2002-03-01 | 2008-04-10 | Sloan-Kettering Institute For Cancer Research | Prevention of recurrence and metastasis of cancer |
US8927251B2 (en) | 2002-10-07 | 2015-01-06 | The University Of Chicago | Targeting of herpes simplex virus to specific receptors |
US7473418B2 (en) * | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
JP2008518599A (ja) | 2004-10-28 | 2008-06-05 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 脊髄損傷疼痛のための末梢送達グルタミン酸脱炭酸酵素遺伝子治療 |
DK2002003T3 (en) | 2005-05-27 | 2016-03-21 | Ospedale San Raffaele Srl | Gene vector comprising miRNA |
US20080008686A1 (en) | 2006-07-10 | 2008-01-10 | The Brigham And Women's Hospital, Inc. | Tetracycline repressor regulated oncolytic viruses |
CA2687301C (en) | 2007-05-09 | 2016-08-23 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses type-1 for treatment of cancers |
US20080289058A1 (en) | 2007-05-14 | 2008-11-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Targeted delivery of glycine receptors to excitable cells |
WO2009111892A1 (en) | 2008-03-14 | 2009-09-17 | Ottawa Health Research Institute | Microrna mediated oncolytic targeting |
PL2700405T3 (pl) * | 2008-05-29 | 2018-08-31 | Alma Mater Studiorum - Università di Bologna | Wirus opryszczki pospolitej (HSV) o zmodyfikowanym tropizmie, jego wykorzystanie i proces przygotowania |
EP2307033A4 (en) | 2008-05-29 | 2012-06-13 | Gen Hospital Corp | USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS |
GB0810912D0 (en) | 2008-06-13 | 2008-07-23 | Inst Animal Health Ltd | Vector |
WO2010105277A1 (en) | 2009-03-13 | 2010-09-16 | Egen, Inc. | Compositions and methods for the delivery of biologically active rnas |
CA2795695A1 (en) * | 2010-04-09 | 2011-10-13 | The University Of Tokyo | Microrna-controlled recombinant vaccinia virus and use thereof |
WO2011130749A2 (en) | 2010-04-16 | 2011-10-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors |
WO2012006181A2 (en) | 2010-06-29 | 2012-01-12 | Mount Sinai School Of Medicine | Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer |
US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
CA2918535A1 (en) | 2013-07-17 | 2015-01-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production |
DK3184641T3 (da) | 2013-10-28 | 2020-08-03 | Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education | Onkolytisk hsv-vektor |
-
2014
- 2014-10-28 DK DK17155129.4T patent/DK3184641T3/da active
- 2014-10-28 KR KR1020167012961A patent/KR102330183B1/ko active IP Right Grant
- 2014-10-28 CN CN201480071446.1A patent/CN106068326B/zh active Active
- 2014-10-28 PT PT171551294T patent/PT3184641T/pt unknown
- 2014-10-28 CA CA2928956A patent/CA2928956A1/en active Pending
- 2014-10-28 US US15/032,958 patent/US10201575B2/en active Active
- 2014-10-28 SG SG11201603119RA patent/SG11201603119RA/en unknown
- 2014-10-28 BR BR112016009465A patent/BR112016009465A8/pt not_active Application Discontinuation
- 2014-10-28 AU AU2014342465A patent/AU2014342465B2/en active Active
- 2014-10-28 WO PCT/US2014/062676 patent/WO2015066042A1/en active Application Filing
- 2014-10-28 ES ES14859119T patent/ES2781852T3/es active Active
- 2014-10-28 NZ NZ720021A patent/NZ720021A/en unknown
- 2014-10-28 EP EP20184441.2A patent/EP3778906A1/en active Pending
- 2014-10-28 MX MX2016005488A patent/MX2016005488A/es unknown
- 2014-10-28 RU RU2016120618A patent/RU2719190C2/ru active
- 2014-10-28 EP EP14859119.1A patent/EP3063279B1/en active Active
- 2014-10-28 KR KR1020217037699A patent/KR102490462B1/ko active IP Right Grant
- 2014-10-28 JP JP2016552209A patent/JP6588024B2/ja active Active
- 2014-10-28 ES ES17155129T patent/ES2810800T3/es active Active
- 2014-10-28 CN CN202110609000.1A patent/CN113717952A/zh active Pending
- 2014-10-28 EP EP17155129.4A patent/EP3184641B1/en active Active
-
2016
- 2016-04-25 IL IL245312A patent/IL245312B/en active IP Right Grant
- 2016-04-27 MX MX2021001158A patent/MX2021001158A/es unknown
- 2016-07-07 US US15/204,350 patent/US10188686B2/en active Active
- 2016-12-14 HK HK16114198A patent/HK1225756A1/zh unknown
-
2017
- 2017-06-07 US US15/616,585 patent/US10172893B2/en active Active
-
2018
- 2018-11-14 US US16/191,141 patent/US10576115B2/en active Active
-
2019
- 2019-09-11 JP JP2019165005A patent/JP6919912B2/ja active Active
-
2020
- 2020-02-05 IL IL272480A patent/IL272480B/en active IP Right Grant
- 2020-08-05 US US16/985,459 patent/US11883448B2/en active Active
-
2021
- 2021-07-15 JP JP2021117410A patent/JP7262134B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016009465A2 (pt) | Vírus herpes simplex oncolítico recombinante (ohsv), ácido nucleico o codificando, estoque viral e composição o compreendendo, bem como seu uso | |
BR112020024863A2 (pt) | Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso | |
BR112019001887A2 (pt) | composições e métodos para o tratamento de doença associada a cep290 | |
CY1121591T1 (el) | Ογκολυτικος ιος απλου ερπητα και θεραπευτικες χρησεις αυτου | |
BR112018013930A2 (pt) | vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus | |
BR112019006384A2 (pt) | enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas | |
SG10201901482XA (en) | Oncolytic adenovirus encoding a b7 protein | |
BR112017013573A2 (pt) | rna de cadeia dupla, sequência de dna, cassete de expressão, vetor de terapia de gene, e, célula hospedeira. | |
BR112018007177A2 (pt) | edição de genoma multiplexado | |
BR112017014917A2 (pt) | elementos regulatórios pós-transcricionais modificados de hepatite | |
BR112017027956A2 (pt) | fator ix modificado e composições, métodos e usos para a transferência de gene para células, órgãos e tecidos | |
MX2017004039A (es) | Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso. | |
BR112017011510A2 (pt) | edição de rna direcionado | |
BR112017007093A2 (pt) | composições e métodos de uso para aumento da resposta imune e terapia do câncer | |
BR112016017736A2 (pt) | métodos e produtos para produção e distribuição de ácido nucleico | |
BRPI0821034A8 (pt) | Vírus influenza b recombinante, seu uso, metodo de preparação, composição de vacina o contendo e seu gene m, bem como ácido nucléico isolado, molécula do vírus influenza m e seu uso e método para aumentar a taxa de crescimento de vírus influenza b deficiente de replicação | |
BRPI0924123B8 (pt) | vetores adenovirais oncolíticos, usos dos mesmos, composição farmacêutica e método para produzir gmcsf em uma célula in vitro | |
BR112017011542A2 (pt) | produção de ácido oleico em levedura | |
WO2018104909A3 (en) | Dna methylation profiling for t-cell immunotherapy | |
BR112019008810A2 (pt) | micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer | |
BR112022002695A2 (pt) | Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso | |
PH12015502096A1 (en) | Thymidine kinase diagnostic assay for gene therapy applications | |
BR112018074472A2 (pt) | interfaces proteicas | |
CL2014003167A1 (es) | Molécula de unión que se une específicamente a inteleuquina 6 (il-6); composición farmacéutica que la comprende; ácido nucleico; vector; célula huésped; y uso para tratar enfermedad o trastorno asociado a il-6. | |
BR112018003238A2 (pt) | seleção de pacientes para terapia de combinação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) |
|
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |